Professors
您现在的位置是: Home >> Staff & Faculty >> Professors >> 正文

  • Xinyong Liu
  •                                                       undefined

    PERSONAL DATA:

    Born: January 7, 1961

    Citizenship:                         China                                                                                                                                                                                    

    Deputy Director, Cheeloo College of Medicine, Shandong University

    Vice Director, National Glycoengineering Research Center, Shandong University

    Director, Institute of Biochemical and Biotechnological Drug, School of Pharmaceutical Sciences, Shandong University

    C8F4

    C8F4

    Xinyong Liu  Ph.D

    C8F4

    Professor of Med. Chem.,

    Director of Medicinal Chemistry Institute;

    Dean of School of Pharmaceutical Sciences, Shandong University

    Head of “Key Laboratory for New Drug Design and Development of Shandong Province

    CURRENT ADRRESS

    Prof. Dr. Xinyong Liu

    Department of Medicinal Chemistry

    School of Pharmaceutical Sciences, Shandong University

    No.44, Wenhuaxi Road , Jinan , 250012 P.R.China

    Tel. 086-531-88380270, 88382005,Fax. 086-531-88382548,

    E-mail: xinyongl@sdu.edu.cn

     

    SOCIAL APPOINTMENTS

    1. Editor and Editorial Board members

    (1) Academic Editor of “Journal of Chemistry”(2012-)

    (2)Editor of “Journal of Applied Pharmaceutical Research (JOAPR)”(2017-2-) http://www.japtronline.com/index.php/JOAPR/about/editorialTeam

    (3) Editorial Advisory Board Member of “Current Medicinal Chemistry” (2010-)

    View Full Editorial Board

    (4)Editorial Board Member of “World Journal of Virology (WJV)” (2011-)

    http://www.wjgnet.com/2220-3249/edboard.htm

    (5)Editorial Board member of Drug Discoveries & Therapeutics”(2011-)

    http://www.ddtjournal.com/EditorialBoard.php

    (6) Editorial Board member of World Journal of Clinical Infectious Diseases”(2011-)

    http://www.wjgnet.com/2220-3176/edboard.htm

    (7)Editorial Board member of “World Journal of Pharmacology” (2011-)

    http://www.wjgnet.com/2220-3192/edboard.htm

    (8) Editorial Board member of “Virology Discovery” (2012-)

    (9) Editorial Board member of journal Interactive Medicinal Chemistry”(2013-)

    (10) Editorial Board member of the “Hans Journal of Medicinal Chemistry” (HJMC). (2013-)

    (11) Editorial Board of the “Journal of Modern Medicinal Chemistry(2013-)

    (12) Editorial Board Member of “Edorium Journal of Drug Research” (2013-)

    (13)Editorial board member of “Pharmacologia” (2013-).

    http://pharmacologia.co.uk/eboard.php

    (14) Editorial Board member of “Journal of Biochemistry and Molecular Biology Research(2014-)

    (15)Editorial Board member of “World Journal of Medicinal Chemistry” (WJMC) (2014-)

    (16)Editorial Board member of Journal of Pharmacology & Pharmacogenomics(2014-)

    (17)Editorial Board member of “Letters in Drug Design & Discovery (LDDD (2014-)

    (18)Editorial Board member of Journal of Drug Design and Research (2014-) http://www.jscimedcentral.com/DrugDesign/editors.php

    (19)Editorial Board member of Journal of AIDS and HIV Infections”.(2014-) click here to view

    (20) Editorial Board member of Drug Design Methodologies and Modern Medicinal Chemistry (2015-) DDMMMC - Editorial Board

    (21) Editorial Board member of Chinese Journal of Pharmaceuticals (2011-)

    (22) Editorial Board member of Journal of Chinese Pharmaceutical Sciences (2014-)

    (23) Editorial Board member of “Journal of Shandong University (Health Science)”(2011-)

    (24)Editorial Board member of “Chinese Journal of Medicinal Chemistry”(2010-)

    (25) Editorial Board member of “Chinese Journal of Pharmaceutical Research”(2014-)

    (26) Editorial Board member of “Journal of Pharmaceutical Research (2015-)

    (27) Editorial Board member of “ Shandong Chemical Industry (2015-)

    (28) Editorial Advisory Board Member ofMedicinal chemistry (2015-)  

    View Full Editorial Board

    (29) Editorial Advisory Board member of the Jacobs Journal of Organic Chemistry. (May 15, 2016--)   http://organicchemistry.jacobspublishers.com/

    (30) As an Editor for the Journal of Pharma & Pharmaceutical Sciences. http://verizonaonlinepublishing.com/PharmaEditors.aspx (Jun 13, 2016 --)

    (31)Editorial Advisory Board Member of Current Research on HIV/AIDS.(Aug.3,2016-)

     http://gavinpublishers.com/research-hivaids-editorial-board

    (32)Editor of “Journal of Applied Pharmaceutical Research (JOAPR)” (2017-2-) http://www.japtronline.com/index.php/JOAPR/about/editorialTeam

     

    2. Social Appointments and Honorary Titles

    (1) Scientist Enjoying Special Government Allowances of the State Council of China (2011-)

    (2) Executive Member of Shandong Pharmaceutical Association (2012-)

    (3) Vice general secretary of Shandong Provincial Pharmaceutical Association (2012-)

    (4)Executive Member of The Shandong Provincial Health Care Council(2007-)

    (5) Awarded as Shandong Provincial Outstanding Medical Academic Professional (2009-)

    (6) The member of the council of Pharmaceutical Association, Shandong Provincine

    (7) Membership of Medicinal Chemistry Committee of Shandong (2008-).

    (8) Awarded as Young Talent of Shandong Province in Science and Technology achievements (2004)

    (9) Awarded as Young Star of Sci and Tech. of Jinan City , Shandong Province (2000).  

    (10) Peer Reviewer for the National Natural Science Foundation of China (2003-)

    (11) Peer Reviewer for the Foundation of Istituto Pasteur-Fondazione Cenci Bolognetti, supporting research in the scientific domains typical of the Institut Pasteur in Paris ( 2012-)

    (12) Grant Review Board and Referee Panel for Health and Medical Research Fund (HMRF), administered by the Food and Health Bureau of the Government of the Hong Kong SAR (2012-)

    (13) Chairman of medicinal chemistry e, Shandong Province (2016-9)

    (14)Vice Chairman of Shandong Provincial Committee for rational drug use (2016-11))

    EDUCATION

    Ph.D.2001-2004, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University

    M.S. 1988-1991, Deparment of Medicinal Chemistry, Shandong Medical University .

    B.S. 1980-1984, College of Pharmacy , Shandong Medical University. 

     

    PROFESSIONAL EXPERIENCE

    2001-Present, Principal Professor, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University .

    1999-2001,  Associate Professor, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University .

    1997-1999, Visiting Scholar, at Institute of Medicinal Chemistry , Consejo Superior de Investigaciones Cientificas (CSIC) of Espania , Madrid , Spain .

    1994-1997,  Associate Professor, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong Medical University .

    1988-1994,  Lecturer, Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong Medical University .

    TEACHING COURSES

    1. For Master students: “Advanced Organic Chemistry”, “Separation and Purification techniques in organic Synthesis”

    2. For undergraduates: “Bioorganic Chemistry”, “Organic Synthesis”,Pharmaceutical English

     

    RESEARCH INTERSTE

    1. Our research work is partly engaged in the rational drug design, synthesis and antiviral evaluation of a variety of molecules that interact with specific enzymes and receptors in viral life cycle (HIV, HBV, HCV, FluV). Presently, (1) in anti-HIV drug research, we are focusing on the design and synthesis of novel non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs), and the new HIV-1 transactivation inhibitors based on HIV-1Tat-TAR interaction in the viral transcription step, as well as the novel multiple ligands (inhibitors) simultaneously targeting at HIV-1 RT and integrase (IN). (2) In anti-HBV drug research, we are focusing on some novel nucleoside inhibitors targeting HBV DNA polymerase and non-nucleoside inhibitors targeting HBV nucleocapsids.(3) In anti-HCV drug research, we are focusing on novel inhibitors against NS5B RNA polymerase. (3) in anti-influenza drug research, we are conducting the neuramidinase inhibitors and RNA polymerase inhibitors and RNA polymerase inhibitors.

    2. Our second ongoing program is undertaken drug discovery and development for treatment of cardio/vascular diseases. (1) Design, synthesis and anticoagulants activity studies of novel factor Xa inhibitors. (2) Synthesis of some natural products from Chinese Traditional Medicine active in cardio/vascular diseases. Presently we are focusing on molecular modification and structure-activity relationships of Ligustrazine derivatives.

    3. Our third ongoing program is dealing with drug delivery research on PEGylated small molecules.

     

    RESEARCH FOUNDING

    1. Design, synthesis and biological evaluation of nucleotides containing thiadiazine bases as HIV reverse transcriptase inhibitors. Key Project of International Collaboration project of National Natural Science Foundation of China, No.81420108027, 2015.1-2019.12

    2. Design, synthesis and biological evaluation of some novel DAPY derivatives bearing six-membered central heterocycles as potent HIV-1 NNRTIs with improved resistant profiles. National Natural Science Foundation of China . No. 81273354, 2013.01-2016.12

    3. Design, synthesis and biological evaluation of Novel HEPT derivatives as HIV-1 No-nucleoside reverse transcriptase inhibitors (NNRTIs). Key Project of International Collaboration project of National Natural Science Foundation of China., No.30910103908; 2010.01-2013.12

    4. Preclinical studies of Ligustrazinyl ferulate as potent anti-ischemic agent, State Key projects for science and technology development.(drug candidates branch), No. 2009ZX09103-117, 2009-2012

    5. Structure-Based Design and synthesis of Multivalent Ligands against HIV-1 replication. Excellent Young Chinese Foreigner Project of National Natural Science Foundation of China . No.30928031, 2010.01-2012.12

    6. Design, synthesis and biological evaluation of substituted thiadiazine derivatives as HIV-1 No-nucleoside reverse transcriptase inhibitors (NNRTIs). National Natural Science Foundation of China . No. 30873133; 2009.1-2011.12

    7. Design, synthesis and biological evaluation of pyrrozothiatriazine derivatives as HIV-1 NNRTIs . National Natural Science Foundation of China . (No. 30371686), 2008.1--2010.12.

    8. Design, synthesis and biological evaluation of Novel HEPT derivatives as HIV-1 NNRTIs. Key Project of Chinese educational ministry, No.30910103908; 2010.01-2013.12

    9. Design, synthesis of novel substituted heterocyle-fused thiatriazine derivatives and their inhibitory activity against HIV-1 reverse transcriptase. PhD supervisor foundation of Chinese educational ministry. (No. 20070422083), 2008.1--2010.12 

    10. Cerebro/Cardiovascular Drug Research and Development of Novel Ligustrazine Derivatives. Rsearch project of Sci.Tech Bureau of Shandong Province (No. 2006GG2202063) 2007.1-2010.1

    11. Preparation and pharmacokinatics of HIV-1 reverse transcriptase inhibitor AZT conjugates. Key Project of Sci.Tech Bureau of Jinan City (No. 200705100), 2007.10--2010.10

    12. Synthesis and Anti-HIV Activity Evaluation of Heterocycle-fused Thiadiazine Derivatives. National Natural Science Foundation of China . (No. 30371686), 2004.1--2006.12

    13. Heterocycle-fused Thiadiazine Derivatives: Synthesis and Screening of Novel HIV-1 NNRTIs.  Key Project of International Collaboration, Chinese Sci.Tech Ministry. (No.2003DF000033) 2004.1-2007.1

     

    RECENT PUBLICATION

    2016

    1.  Kang, Dongwei; Fang, Zengjun; Li, Zhenyu; Huang, Boshi; Zhang, Heng; Lu, Xueyi; Xu, Haoran; Zhou, Zhongxia; Ding, Xiao; Daelemans, Dirk; De Clercq, Erik; Pannecouque, Christophe*; Zhan, Peng*; Liu, Xinyong*. Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. J Med Chem. 2016, 59(17):7991-8007.

    2.  Zhan, Peng; Pannecouque, Christophe; De Clercq, Erik*; Liu, Xinyong*. Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. J Med Chem. 2016, 59(7):2849-78.

    3.  Chen, Wenmin; Zhan, Peng; Daelemans, Dirk; Yang, Jiapei; Huang, Boshi; De Clercq, Erik; Pannecouque, Christophe*; Liu, Xinyong*. Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. Eur J Med Chem. 2016, 121:352-63.

    4.  Yang, Jiapei; Chen, Wenmin; Kang, Dongwei; Lu, Xueyi; Li, Xiao; Liu, Zhaoqiang; Huang, Boshi; Daelemans, Dirk; Pannecouque, Christophe; De Clercq, Erik; Zhan, Peng*; Liu, Xinyong*. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. Eur J Med Chem. 2016, 109:294-304.

    5.  Jia, Haiyong; Bai, Fuxiang; Liu, Na; Liang, Xiaohong; Zhan, Peng; Ma, Chunhong;  Jiang, Xuemei; Liu, Xinyong*. Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors. Eur J Med Chem. 2016, 123:202-10.

    6.  Meng, Qing; Chen, Xuwang; Kang, Dongwei; Huang, Boshi; Li, Wenxin; Zhan, Peng; Daelemans, Dirk; De Clercq, Erik; Pannecouque, Christophe*; Liu, Xinyong*. Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. Eur J Med Chem. 2016, 115:53-62.

    7.  Li, Xiao; Gao, Ping; Huang, Boshi; Zhou, Zhongxia; Yu, Zhao; Yuan, Zheng; Liu, Huiqing; Pannecouque, Christophe; Daelemans, Dirk; De Clercq, Erik; Zhan, Peng*; Liu, Xinyong*. Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. Eur J Med Chem. 2016;126:190-201.

    8.  Kang, Dongwei; Zhang, Heng; Zhou, Zhongxia; Huang, Boshi; Naesens, Lieve*; Zhan, Peng*; Liu, Xinyong*. First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via 'privileged scaffold' refining approach. Bioorg Med Chem Lett. 2016, 26(21):5182-6.

    9.  Lu, Xueyi; Li, Xiao; Yang, Jiapei; Huang, Boshi; Kang, Dongwei; Zhao, Fabao; Zhou, Zhongxia; De Clercq, Erik; Daelemans, Dirk; Pannecouque, Christophe*; Zhan, Peng*;  Liu, Xinyong*. Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. Bioorg Med Chem. 2016, 24(18):4424-33.

    10.     Li, Wenxin; Huang, Boshi; Kang, Dongwei; De Clercq, Erik; Daelemans, Dirk; Pannecouque, Christophe; Zhan, Peng*; Liu, Xinyong*. Design, synthesis, and biological evaluation of novel 5-Alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse-transcriptase inhibitors. Chem Biol Drug Des. 2016,   88(3):380-5.

    11.     Li, Xiao; Huang, Boshi; Zhou, Zhongxia; Gao, Ping; Pannecouque, Christophe; Daelemans, Dirk; De Clercq, Erik; Zhan, Peng*; Liu, Xinyong*. Arylazolyl(azinyl)thioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach. Chem Biol Drug Des. 2016, 88(2):241-53.

    12.     Huang, Boshi; Li, Xiao; Zhan, Peng*; De Clercq, Erik; Daelemans, Dirk; Pannecouque, Christophe; Liu, Xinyong*. Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. Chem Biol Drug Des. 2016, 87(2):283-9.

    13.     Xu, Haoran; Fu, Lu; Zhan, Peng*; Liu, Xinyong*. 3D-QSAR analysis of a series of S-DABO derivatives as anti-HIV agents by CoMFA and CoMSIA. SAR QSAR Environ Res. 2016, 1-16.

    14.     Sun, Lin; Gao, Ping; Zhan, Peng*; Liu, Xinyong*. Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182. Expert Opin Ther Pat. 2016, 26(9):979-86.

    15.     Gao, Ping; Sun, Lin; Zhou, Junsu; Li, Xiao; Zhan, Peng*; Liu, Xinyong*. Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach. Expert Opin Drug Discov. 2016, 11(9):857-71.

    16.     Zhang, Heng; Kang, Dongwei; Huang, Boshi; Liu, Na; Zhao, Fabao; Zhan, Peng*; Liu, Xinyong*. Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities. Eur J Med Chem. 2016, 114:65-78.

    17.     Li, Xiao; Gao, Ping; Zhan, Peng*; Liu, Xinyong*. Substituted indoles as HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent evaluation (WO2015044928). Expert Opin Ther Pat. 2016, 26(5):629-35.

    18.     Huang, Boshi; Kang, Dongwei; Yang, Jiapei; Zhan, Peng*; Liu, Xinyong*. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. Expert Opin Ther Pat. 2016, 26(2):281-9.

    19.     Huang, Boshi; Zhou, Zhongxia; Kang, Ddongwei; Li, Wanzhuo; Chen, Zihui; Zhan, Peng*; Liu Xinyong*. Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). Expert Opin Ther Pat. 2016 Nov 25:1-7.

    20.     Wang, Xueshun; Huang, Boshi; Liu, Xinyong*; Zhan, Peng*. Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. Drug Discov Today. 2016, 21(1):118-32.

    21.     Zhan, Peng; Wang, Xueshun; Liu, Xinyong*; Suzuki, Takayoshi*. Medicinal chemistry insights into novel HDAC inhibitors: An updated patent review (2012-2016). Recent Pat Anticancer Drug Discov. 2016.

    22.     Huang, Boshi; Liu, Xinhao; Li, Wanzhuo; Chen, Zihui; Kang, Dongwei; Zhan, Peng*; Liu, Xinyong*. An improved synthesis approach of the HIV-1 inhibitor RDEA427, a pyrrolo[2,3-d]pyrimidine derivative. ARKIVOC. 2016;6:45 - 51.

    23. Zhan Peng, Wang Xueshun, Liu Xinyong. Contemporary Molecular Targeted Drug in the Context of “Precision Medicine”: An Attempting Discussion of “Precision Drug Design”. Progress in Chemistry, 2016, 28(9): 1363-1386

     

    2015

    1. Zhan, Peng; Itoh, Yukihiro; Suzuki, Takayoshi*; Liu, Xinyong*. Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators. J Med Chem 2015, 58, 7611-33.

    2. Boshi Huang; Cuicui Li; Wenmin Chen; Tao Liu; Mingyan Yu; Lu Fu; Yueyue Sun; Huiqing Liu; Erik De Clercq; Christophe Pannecouque; Jan Balzarini; Peng Zhan; Xinyong Liu*. Fused Heterocycles Bearing Bridgehead Nitrogen as Potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]Triazolo[1,5-a]pyrimidine Core via Structure-based and Physicochemical Property-driven Approaches. European Journal of Medicinal Chemistry. 201592754-765 (DOI information: 10.1016/j.ejmech.2015.01.042)

    3. Boshi Huang; Xin Liang; Cuicui Li; Wenmin Chen, Tao Liu; Xiao Li; Yueyue Sun; Lu Fu; Huiqing Liu, Erik De Clercq, Christophe Pannecouque, Peng Zhan*, Xinyong Liu*. Fused Heterocycles Bearing Bridgehead Nitrogen as Potent HIV-1 NNRTIs. Part 4: Design, Synthesis and Biological evaluation of Novel Imidazo[1,2-a]pyrazines. European Journal of Medicinal Chemistry, 2015; 93: 330-337. (doi: 10.1016/j.ejmech.2015.02.022)

    4. Yu’ning Song, Hao Xu, Wenmin Chen, Peng Zhan,*, Xinyong Liu* 8-Hydroxyquinoline: A Privileged Structure with Broad-ranging Pharmacological Potentials. Medicinal Chemistry Communications. 2015; 6: 61-74

    5. Tao Liu, Boshi Huang, Ye Tian, Xin Liang, Hong Liu, Huiqing Liu, Peng Zhan*, Erik De Clercq, Christophe Pannecouque and Xinyong Liu*. Design, Synthesis, and Biological Evaluation of Novel 4-Aminopiperidinyl-linked 3,5-Disubstituted-1,2,6-thiadiazine-1,1-dione Derivatives as HIV-1 NNRTIs. Chemical Biology & Drug Design , Chem Biol Drug Des, 2015; 86, 107-13.

    6. Xuwang Chen, Qing Meng, Peng Zhan, Huiqing Liu, Erik De Clercq, Christophe Pannecouque and Xinyong Liu*. Design, Synthesis and Anti-HIV Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the NNRTI Binding Pocket. Chemical Biology & Drug Design. 2015; 86, 122-8.

    7. Zengjun Fang, Dongwei Kang, Lingzi Zhang, Boshi Huang, Huiqing Liu, Christophe Pannecouque, Erik De Clercq, Peng Zhan* and Xinyong Liu*. Synthesis and Biological Evaluation of a Series of 2-((1-substituted-1H-1,2,3-triazol-4-yl)methylthio)-6-(naphthalen-1- ylmethyl)pyrimidin-4(3H)-one As Potential HIV-1 Inhibitors Chemical Biology & Drug Design. 2015; 86, 614-8.

    8. Zhang, Lingzi; Guo, Jian; Liu, Xin; Liu, Huiqing; De Clercq, Erik; Pannecouque, Christophe; Liu, Xinyong*. Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents. Chem Biol Drug Des 2015, 86, 333-43.

    9.Kang, Dongwei; Fang, Zengjun; Huang, Boshi; Zhang, Lingzi; Liu, Huiqing.; Pannecouque, Christophe; Naesens, Laesens; De Clercq, Erik; Zhan, Peng; Liu, Xinyong*. Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections. Chem Biol Drug Des 2015, 86, 568-77.

    10. Diwakar Rai, Liu Wang, Xuemei Jiang*, Peng Zhan, Haiyong Jia, Erik De Clercq, and Xinyong Liu* The changing face of Hepatitis C: Recent Advances on HCV Inhibitors Targeting NS5A. Current Medicinal Chemistry, 2015; 22(15): 1860-1879.

    11. Wang Xueshun, Huang Boshi, Suzuki Takayoshi*, Liu Xinyong*; Zhan Peng*. Medicinal chemistry insights in the discovery of novel LSD1 inhibitors. Epigenomics 2015; 7, 1379-96.

    12. Na Liu, Fabao Zhao, Haiyong Jia, Diwakar Rai, Peng Zhan*, Xuemei Jiang* and Xinyong Liu*. Non-nucleoside anti-HBV agents: Advances in structural optimization and mechanism of action investigations. MedChemComm. 2015; 6( 4): 521-535

    13. Fabao Zhao, Na Liu, Peng Zhan*, Xuemei Jiang* and Xinyong Liu*. Discovery of HCV NS5B Thumb Site I Inhibitors: Core-refining from Benzimidazole to Indole Scaffold. European Journal of Medicinal Chemistry. 2015; 94: 218-228, EJMECH-D-14-02281R1

    14. Haiyong Jia, Diwakar Rai, Xuwang Chen, Peng Zhan*, Xuemei Jiang,* and Xinyong Liu*. Recent Advance of the Hepatitis B Virus Inhibitors: a Medicinal Chemistry Overview. Future Medicinal Chemistry, 2015; 7(5):587-607. doi: 10.4155/fmc.15.19

    15. Na Liu, Fabao Zhao, Peng Zhan and Xinyong Liu*. Review of Small Synthetic Molecules Targeting HBV Capsid Assembly. Medicinal Chemistry. 2015;11(8):710-716, DOI: 10.2174/157340641108151029111243

    16. Liu, Xin; Chen, Xuwang; Zhang, Lingzi; Zhan, Peng; Liu, Xinyong*. 3D-QSAR and docking studies on piperidine-substituted diarylpyrimidine analogues as HIV-1 reverse transcriptase inhibitors. Med Chem Res. 2015; 24: 3314-3326

    17. Li, Wenlong; Liu, Huiqing; Wei, Chunmin; Wei, Xinbing; Tang, Mingtian; Kong, Xianlin; Chen, Hongfei; Liu, Xinyong; Guo, Ruichen*. Pharmacokinetics and metabolism of Chf197, a ligustrazine derivative, in rats. Fundam Clin Pharmacol 2015, 29, 478-87.

    18.Yan, Shi; Chen, Lin; Wei, Xinbing; Cheng, Li; Kong, Lingjun; Liu, Xinyong; Zhang, Xiumei.; Liu, Huiqing. Tetramethylpyrazine analogue CXC195 ameliorates cerebral ischemia-reperfusion injury by regulating endothelial nitric oxide synthase phosphorylation via PI3K/Akt signaling. Neurochem Res 2015, 40, 446-54.

    19. Zhao Fabao, Liu Na, Zhan Peng*, Jiang Xuemei*, Liu Xinyong*. Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold. Eur J Med Chem 2015, 94, 218-28.

    20. Wenxin Li, Xiao Li, Erik De Clercq, Peng Zhan, Xinyong Liu*. Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif. European Journal of Medicinal Chemistry. 2015; 102:167-179

    21. Qing Meng, Na Liu, Boshi Huang, Peng Zhan* & Xinyong Liu*. Novel fluorine-containing DAPY derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2014072419. Expert Opin Ther Pat 2015; 25, 1477-86.

    22. Boshi Huang, Kang Dongwei, Zhan Peng*, Liu Xinyong*. Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. Expert Opin Drug Discov 2015; 10, 1271-81.

    23.Xinyong Liu. Meet the Editorial Board Member, Letters in Drug Design & Discovery, 2015; 12: 519 - 520

     

    2014

    1. Yuanchao Xie, Dongqing Xu, Bing Huang, Xiuli Ma, Wenbao Qi, Fangyuan Shi, Xinyong Liu,*, Yingjie Zhang*, and Wenfang Xu*.  Discovery of NSubstituted Oseltamivir Derivatives as Potent and Selective Inhibitors of H5N1 Influenza Neuraminidase. Journal of Medicinal Chemistry, 2014, 57 (20): 8445–8458

    2. Liu Wang, Ye Tian, Wenmin Chen, Hong Liu, Peng Zhan, Dongyue Li, Huiqing Liu, Erik De Clercq, Christophe Pannecouque, Xinyong Liu*. Fused Heterocyclic Compounds Bearing Bridgehead Nitrogen as Potent HIV-1 NNRTIs. Part 2: Discovery of Novel [1,2,4]Triazolo[1,5-a] pyrimidines Using A Structure-guided Core-refining Approach. European Journal of Medicinal Chemistry, 201485:293-303

    3. Tao Liu, Boshi Huang, Peng Zhan, Erik De Clercq, Xinyong Liu*. Discovery of small molecular inhibitors targeting HIV-1 gp120–CD4 interaction derived from BMS-378806. European Journal of Medicinal Chemistry, 201486: 481-490

    4. Jun Wang, Peng Zhan, Zhenyu Li, Huiqing Liu, Erik De Clercq, Christophe Pannecouque, Xinyong Liu. Nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry. 2014, 76 (9 April): 531–538

    5. Xiao Li, Wenmin Chen, Ye Tian, Huiqing Liu, Peng Zhan, Erik De Clercq, Christophe Pannecouque, Jan Balzarini, Xinyong Liu. Discovery of Novel Diarylpyrimidines as Potent HIV NNRTIs via A Structure-guided Core-refining Approach. European Journal of Medicinal Chemistry, 2014; 80: 112-121.

    6. Yu’ning Song, Xiaoqian Lin, Dongwei Kang, Xiao Li, Peng Zhan*, Xinyong Liu*, Qingzhu Zhang*, Discovery and Characterization of Novel Imidazopyridine Derivative CHEQ-2 as A Potent CDC25 Inhibitor and Promising Anticancer Drug Candidate. European Journal of Medicinal Chemistry. 2014; 82: 293-307.

    7. Liu Zhaoqiang, Wenmin Chen, Peng Zhan*, Erik De Clercq, Christophe Pannecouque, Xinyong Liu*. Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided hybridization", European Journal of Medicinal Chemistry, 2014; 87: 52-62

    8. Xiao Li, Xueyi Lu, Wenmin Chen , Huiqing Liu , Peng Zhan*, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic & Medicinal Chemistry. 2014; 22(19): 52905297.

    9. Lingzi Zhang, Peng Zhan, Xuwang Chen, Zhenyu Li, Zhoumeng Xie, Tong Zhao, Huiqing Liu, Erick De Clercq, Christophe Pannecouque, Jan Balzarini and Xinyong Liu*. Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. Reference: Bioorganic & Medicinal Chemistry .2014; 22: pp. 633-642

    10. Wenmin Chen, Peng Zhan, Diwakar Rai, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Huiqing Liu, Zhongxia Zhou, Xinyong Liu*. Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays. Bioorganic & Medicinal Chemistry, 2014; 22: 1863-1872

    11. Ye Tian, Deping Du, Diwakar Rai, Liu Wang, Huiqing Liu, Peng Zhan,*, Erik De Clercq, Christophe Pannecouque, Xinyong Liu,*. Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: Design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. Bioorganic & Medicinal Chemistry, 2014; 22: 2052-2059

    12. Hongfei Chen; Guoning Li, Qian Ding; Lei Cui, Peng Zhan, Shouxun Wang, Xinyong Liu* Design, synthesis and biological evaluation of novel trimethylpyrazine-2-carbonyloxy-cinnamic acids as potent cardiovascular agents. Medicinal Chemistry Communications., 2014, 5, 711-718

    13. Diwakar Rai, Wenmin Chen, Peng Zhan, Hong Liu, Ye Tian, Xin Liang, Erik De Clercq, Christophe Pannecouque, Jan Balzarini, and Xinyong Liu*. Synthesis and Anti-HIV Activity of 4-(Naphthalen-1-yl)-1,2,5-thiadiazol-3-hydroxyl Derivatives. Chemical Biology & Drug Design, 2014; 84: 420–430

    14. Zengjun Fang, Yu’ning Song, Qingzhu Zhang, Peng Zhan* & Xinyong Liu*. Conformational restriction: an effective tactic in 'follow-on'-based drug discovery. Future Medicinal Chemistry. 2014; 6(8):885-901.

    15. Zhenyu Li, Fang Yu, Lei Cui, Wenmin Chen, Shouxun Wang, Peng Zhan, Yuemao Shen and Xinyong Liu*. Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents. Medicinal Chemistry. 2014; 10( 1): 81-89

    17. Jun Wang, Yan Wang, Rujun Bai, Peng Zhan, Christophe Pannecouque Jan Balzarini, Erik De Clercqb, Xinyong Liu*. Design, Synthesis and Biological Evaluation of Substituted Guanidine Indole Derivatives as Potential Inhibitors of HIV-1 Tat-TAR Interaction. Med Chem. 2014;10(7):738-46.

    17. Yu’ning Song, Zengjun Fang, Peng Zhan and Xinyong Liu. Recent Advances in the Discovery and Development of Novel HIV-1 NNRTI Platforms (Part II): 2009-2013 Update#. Current Medicinal Chemistry. 2014; 21(3): 329-355.

    18. Lili Cao, Peng Zhan*, Weiguo Song, Erik De Clercq, and Xinyong Liu*. Recent progress in the research of small molecule HIV-1 RNase H inhibitors. Current Medicinal Chemistry. 2014; 21(17): 1956-1967

    19. Ye Tian, Dujuan Zhang, Peng Zhan and Xinyong Liu*. Medicinal Chemistry of Small Molecule CCR5 Antagonists for Blocking HIV-1 Entry: A Review of Structural Evolution. Current Topics in Medicinal Chemistry (CTMC). 2014;14(13):1515-1538

    20. Xiao Li, Lingzi Zhang, Ye Tian, Yu’ning Song, Peng Zhan, and Xinyong Liu. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011–2014). Expert Opin Ther Pat. 2014; 24(11): 1199-227  (doi:10.1517/13543776.2014.964685)

    21. Yu’ning Song, Wenmin Chen, Dongwei Kang, Peng Zhan* and Xinyong Liu*. “Old Friends in New Guise”: Exploiting Privileged Structures for Scaffold Re-Evolution/Refining. Combinatorial Chemistry & High Throughput Screening, 2014, 17(6): 536-53.

    22. Dongwei Kang, Yuning Song, Wenmin Chen, Peng Zhan*, Xinyong Liu* . “Old Dogs with New Tricks”: Exploiting Alternative Mechanisms of Action and New Drug Design Strategies for Clinically Validated HIV Targets. Molecular BioSystems, 2014; 10(8): 1998-2022.

    Impact Factor: 3.35). 05/2014; DOI:10.1039/c4mb00147h.

    23. Zhan Peng*, Song Yunning, Itoh Y, Suzuki T*, Liu Xinyong*. Recent advances in the structure-based rational design of TNKSIs. Molecular Biosyst. 2014, 10(11): 2783-2799.

    24. Lin Chen, Xinbing Wei, Yunfeng Hou, Xiaoqian Liu, Senpeng Li, Baozhu Sun, Xinyong Liu, Huiqing Liu. Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion-induced apoptosis through PI3K/Akt/GSK3β pathway in rats. Neurochemistry International. 2014; 66(1): 27-32  (Impact Factor 2.66)

    25. Chen J, Wang W, Wang H, Liu X, Guo X. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis. Drug Discov Ther. 2014; 8(1): 33-41.

    26. Zhang, Peng; Zheng, Bei-Bei; Wang, Hong-Yuan; Chen, Jin-Hua; Liu, Xin-Yong; *Guo, Xiu-Li, DLJ14, a novel chemo-sensitization agent, enhances therapeutic effects of adriamycin against MCF-7/A cells both in vitro and in vivo, Journal of Pharmacy and Pharmacology, 66(3), pp 398-407, 2014/3.

     

    2013

    1. Wenjun Li, Peng Zhan, Erik De Clercq, Hongxiang Lou*, Xingyong Liu*. Current Drug research on PEGytion with small molecular agents. Progress in Polymer Science, 2013; 38: 421-444. (IF= 26.383)

    2. Peng Zhan, Xuwang Chen, Dongyue Li, Zengjun Fang, Erik De Clercq, Xinyong Liu*. HIV-1 NNRTIs: Structural diversity, pharmacophore similarity, and implications for drug design. Medicinal Research Review, 2013; 33(S1): E1-E72  (IF=9.583)

    3. Ye Tian, Diwakar Rai, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Huiqing Liu, Xinyong Liu*. Design, synthesis and biological evaluation of novel 3,5-disubstituted-1,2,6-thiadiazine-1,1-dione derivatives as HIV-1 NNRTIs (CBDD-RA- 02-13-1571 ) . Chemical Biology & Drug Design. 2003: 82(4):384-93

    4. Wenmin Chen, Peng Zhan, Erik De Clercq, Christophe Pannecouque, Jan Balzarini, Xin Jiang, Xinyong Liu*. Design, synthesis and biological evaluation of N2, N4-disubstituted- 1,1,3-trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatriazine derivatives as HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry. 2013; 21(22):7091-7100

    5. Diwakar Rai,Wenmin Chen, Ye Tian, Xuwang Chen,Peng Zhan, Erik De Clercq, Christophe Pannecouque, Jan Balzarinib, Xinyong Liu*. Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry. 2013; 21: 7398–7405 (Reference: BMC11135)

    6. Dongyue Li, Peng Zhan, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry. 2013; 21(7): 2128-2134.

    7. Yu’ning Song, Peng Zhan,* Dongwei Kang, Xiao Li, Ye Tian, Zhenyu Li, Xuwang Chen,   Wenmin Chen, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Discovery of novel pyridaziylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. Medicinal Chemistry Communications. 2013; 4(5): 810-816 

    8. Xuwang Chen; Erik De Clercq; Shufang Ding; Yuanyuan Li; Huiqing Liu; Jan Balzarini; Christophe Pannecouque; Xinyong Liu*. Discovery of Piperidine-Linked Pyridine Analogues as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors. ChemMedChem, 2013; 8(7): 1117–1126

    9. Hongfei Chen, Guoning Li, Peng Zhan, Xiuli Guo, Qian Ding, Shouxun Wang and Xinyong Liu*. Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. MedChemCommun., 2013, 4, 827-832

    10. Xuwang Chen,Xin Liu, Qing Meng, Ding Wang, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq and Xinyong Liu*. Novel Piperidinylamino-diarylpyrimidine Derivatives with Dual Structural Conformations as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Bioorganic & Medicinal Chemistry letter. 2013; 23(24): 6593–6597

    11. Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque , Erik De Clercq, Xinyong Liu*. Synthesis and anti-HIV evaluation of novel 1,2,4-triazole derivatives as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. Letters in Drug Design & Discovery, 2013; 10(1): 27-34

    12. Zhenyu Li, Fang Yu, Lei Cui, Wenmin Chen, Shouxun Wang, Peng Zhan, Yuemao Shenx and Xinyong Liu*. Ligustrazine Derivatives. Part 8: Design, Synthesis, and Preliminary Biological Evaluation of Novel Ligustrazinyl Amides as Cardiovascular Agents. Medicinal Chemistry. in press (2013).

    13. Zhenyu Li, Yuan Cao, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Yuemao Shen and Xinyong Liu*. Arylazolylthioacetanilide. Part 11: Design, synthesis and biological evaluation of 1,2,4-triazole thioacetanilide derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Medicinal Chemistry, 2013, 9 (6)968-973

    14. Lingzi Zhang, Peng Zhan, Xuwang Chen, Zhenyu Li, Zhoumeng Xie, Tong Zhao, Huiqing Liu, Erick De Clercq, Christophe Pannecouque, Jan Balzarini and Xinyong Liu*. Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. Reference: Bioorganic & Medicinal Chemistry BMC 11184, accepted

    15. Yuning Song; Peng Zhan*; Erik De Clercq; Xiao Li; Diwakar Rai; Xinyong Liu*. Multivalent agents: a novel concept for anti-HIV drug discovery. Current Medicinal Chemistry, 2013, 20(6): pp. 815-832

    16. Yuning Song, Peng Zhan* and Xinyong Liu*. Heterocycle-thioacetic Acid Motif: A Privileged Molecular Scaffold with Potent, Broad-Ranging Pharmacological Activities. Curr Pharm Des. 2013;19: 7141-7154

    17. Yu'ning Song, Peng Zhan, Qingzhu Zhang and Xinyong Liu*. Privileged Scaffolds or Promiscuous Binders: A Glance of Pyrrolo[2,1-f][1,2,4]triazines and Related Bridgehead Nitrogen Heterocycles in Medicinal Chemistry. Current Pharmaceutical Design. 2013; 19(8): 1528-1548

    18. Peng Zhan* and Xinyong Liu*. Rationally designed multitarget anti-HIV agents. Current medicinal chemistry, 2013; 20(13): 1743-58.

    19. Xuwang Chen, Shufang Ding, Peng Zhan and Xinyong Liu*. Recent Advances of Diaryl Ether Family as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors. Current Pharmaceutical Design. 2013; 19(15): 2829-2838

    20. Dongwei Kang, Yu’ning Song, Peng Zhan, Qingzhu Zhang, Xinyong Liu*. Design, synthesis and acetylcholinesterase (AChE) inhibition assay of novel 9-(1-(substituted-benzyl) piperidin-4-yl)-2-chloro-9H-purin-6-amine derivatives. Journal of Chemistry. 2013; Volume 2013, Article ID 107302, 9 pages (http://dx.doi.org/10.1155/2013/107302) (IF=0.484)

    21. SUN Sang-Dun, MI Si-Qi, YOU Jing, YU Ji-Liang, HU Song-Qing, LIU Xin-Yong*. HQSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors[J]. Acta Phys. Chim. Sin., 2013, 29 (6), 1192-1200

     

    2012

    1. Dongyue Li, Peng Zhan, Erik De Clercq, Xinyong Liu*. Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of six representative candidates. Journal of Medicinal Chemistry, 2012, 55 (8), pp 3595–361. (IF= 5.2) (DOI: 10.1021/jm 200990c )

    2. Xuwang Chen, Peng Zhan, Xin Liu, Ziheng Cheng, Caicai Meng, Siyuan Shao, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*, Design, synthesis, anti-HIV evaluation and molecular modeling of piperidine-linked amino-triazine derivatives as potent non-nucleoside reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry, 2012: 20 : 38563864

    3. Wenjiun Li, Jingde Wu, Peng Zhan, Yu Chang, Christophe Pannecouque, Erik De Clercq & Xinyong Liu*. Synthesis, drug release and anti-HIV Activity of a series of PEGylated zidovudine conjugates. International Journal of Biological Macromolecules. 2012;50(4): 974-980

    4. Xuwang Chen, Peng Zhan, Christophe Pannecouque, Jan Balzarini, Erik De Clercq and Xinyong Liu*. Synthesis and biological evaluation of piperidine-substituted triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2012; 51: 60-66

    5. Peng Zhan, Wenmin Chen, Zhenyu Li, Xiao Li, Xuwang Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Structure-based Bioisosterism Design, Synthesis and Biological Evaluation of Novel 1,2,4-Triazin-6-ylthioacetamides As Potent HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry Letters. 2012; 22: 71557162

    6. Peng Zhan, Wenmin Chen, Zhenyu Li, Xiao Li, Xuwang Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Discovery of Novel 2-(3-(2-Chlorophenyl) pyrazin-2-ylthio)-N-arylacetamides As Potent HIV-1 Inhibitors Using a Structure-Based Bioisosterism Approach. Bioorganic & Medicinal Chemistry, 2012, Volume 20, Issue 23,   Pages 6795–6802

    7. Xiao Li, Peng Zhan*, Hong Liu, Dongyue Li, Liu Wang , Xuwang Chen, Huiqing Liu, Christophe Pannecouque, Jan Balzarini, Erik De Clercq, Xinyong Liu*. Arylazolyl(azinyl) thioacetanilides. Part 10: Design, synthesis and biological evaluation of novel substituted imidazopyridinylthioacetanilides as potent HIV-1 inhibitors. Bioorganic & Medicinal Chemistry. 2012; 20: 5527-5536

    8. Peng Zhan, Xuwang Chen, Dongyue Li, Zengjun Fang, Erik De Clercq, Xinyong Liu* Arylazolyl(azinyl)thioacetanilide. Part 9: Synthesis and Biological Investigation of      Thiazolylthioacetamides Derivatives as A Novel Class of Potential Antiviral Agents. Archives of Pharmacal Research, 2012;Vol 35, No 6, 975-986,

    9. Lijuan Deng, Xiuli Guo, Li Zhai, Yuning Song, Hongfei Chen, Peng Zhan, Jingde Wu, Xinyong Liu*. Ligustrazine derivatives. Part 4: Design, synthesis and biological evaluation of novel Ligustrazine-based stilbene derivatives as potential cerebrocardiac vascular agents. Chemical Biology & Drug Design. 2012 May ; 79 ( 5 ): 731-739 

    (DOI: 10.1111/j.1747-0285.2012.01332.x)

    10. Wenwen Chen, Peng Zhan, Erik De Clercq and Xinyong Liu*. Recent Progress in Small Molecule CCR5 Antagonists as Potential HIV-1 Entry Inhibitors. Current Pharmaceutical Design, 2012; 18(1): 4165-4186

    11. Zhenyu Li, Peng Zhan, Lieve Naesens, Evelien Vanderlinden, Ailin Liu, Guanhua Du, Erik De Clercq and Xinyong Liu*. Synthesis and preliminary biological evaluation of 5-substituted-2-(4- substituted phenyl) benzoxazoles as a novel class of influenza virus A inhibitors. Chemical Biology & Drug Design. 2012; 79 ( 6 ): 1018-24

    12. Ye Tian, Peng Zhan, Diwakar Rai, Jiyan Zhang, Erik De Clercq and Xinyong Liu*. Recent Advances in the Research of 2,3-Diaryl-1,3-thiazolidin-4-one Derivatives as Potent HIV-1 NNRTIs. Current Medicinal Chemistry, 2012; 19(13): 2026-2037.

    13. Wenmin Chen, Peng Zhan, Jingde Wu, Zhenyu Li and Xinyong Liu*. The Development of HEPT-type HIV Non-Nucleoside Reverse Transcriptase Inhibitors and Its Implications for DABO Family. Current Pharmaceutical Design, 2012, 18, 4165-4186

    14. Xiaofei Jiang, Peng Zhan, Xinyong Liu * & Erik De Clercq. Synthesis and Anti-HIV Activity Evaluation of 2-(5-(Naphthalen-1-yl)-1,2,3-thiadiazol-4-ylthio)-N-acetamides Derivatives. Lat. Am. J. Pharm. 2012; 31 (5): 751-755

    15. Zhenyu Li, Fang Yu, Lei Cui, Peng Zhan, Shouxun Wang* and Xinyong Liu*. Ligustrazine derivatives. Part 6: Design, synthesis and evaluation of novel ligustrazine acylguanidine derivatives as potential cerebrocardiac vascular agents. Medicinal Chemistry. 2012 Jun 25. 2012;8(5):928-33.

    16. Xiao Li, Peng Zhan, Erik De Clercq, Xinyong Liu*. The HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors (Part V): Capravirine and Its Analogues. Current Medicinal Chemistry, 2012; 19 ( 36): Pp.6138-6149

    17. Peng Zhan, Dongyue Li, Junyi Li, Xuwang Chen and Xinyong Liu,* Benzimidazole (Benzimidazolone) Heterocycle as A Privileged Scaffold in Antiviral Agents. Mini-Review in Organic Chemistry, 2012, 9, 397-410

    18. Zhai L, Zhang P, Sun RY, Liu XY, Liu WG, Guo XL.Cytoprotective effects of CSTMP, a novel stilbene derivative, against H2O2-induced oxidative stress in human endothelial cells. Pharmacol Rep. 2012, Nov;63(6):1469-80.

     

    2011

    1. Zhang Jing, Zhan Peng, Wu Jingde, Li Zhenyu, Jiang Yan, Ge Weiying, Pannecouque C, De Clercq E, Liu Xinyong*. Synthesis and biological evaluation of novel 5-alkyl-2-arylthio-6- ((3,4-dihydroquinolin-1(2H)-yl)methyl) pyrimidin-4(3H)-ones as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorganic & Medicinal Chemistry, 2011; 19: 4366–4376

    2. Mingyan Yu, Zhenyu Li, Shuai Liu, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Synthesis and biological evaluation of 6-substituted 5-alkyl-2-(phenylaminocarbonyl -methylthio)pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. ChemMedChem 2011; 6(5): 826–833

    3. Mingyan Yu, Xinyong Liu*, Ailin Liu, Guanhua Du, Lieve Naesens, Evelien Vanderlinden, Erik De Clercq. Discovery of dihydro-alkyloxy-benzyl-oxopyrimidines as promising anti-influenza virus agents. Chemical Biology & Drug Design, 2011, 78(4): 596–602

    4. Peng Zhan, Xuwang Chen, Dongyue Li, Wenwen Chen, Ye Tian, Christophe Pannecouque, Erik De Clercq and Xinyong Liu*. Arylazolylthioacetanilide part 8.  Design, Synthesis and Biological Evaluation of Novel 2-(2-(2,4-Dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N- arylacetamides As Potent HIV-1 Inhibitors. European Journal of Medicinal Chemistry. 2011; 46 : 5039-5045

    5. Zhan Peng, Li Dongyue, Chen Xuwang, Liu Xinyong*, De Clercq Erik. Functional Roles of Azoles Motif in Anti-HIV Agents. Current Medicinal Chemistry, 2011; 18(1): 29-46

    6. Hongfei Chen, Peng Zhan, Xinyong Liu*. Ligustrazine derivatives. Part 5: Design, synthesis and biological evaluation of novel ligustrazinyloxy-cinnamic acid derivatives as potent cardiovascular agents. European Journal of Medicinal Chemistry. 2011;46: 5609-5615

    7. Zhan Peng, Liu Xinyong*. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). Expert Opin. Ther. Patents (2011) ; 21(5):1-80

    8. Jiang Yan, Liu Xinyong*, De Clercq Erik. New Therapeutic Approaches Targeted at the Late Stages of the HIV-1 Replication Cycle. Current Medicinal Chemistry, 2011; 18(1): 16-28

    9. Mingyan Yu, Erkang Fan, Jingde Wu and Xinyong Liu*. Recent Advances in the DABOs Family as Potent HIV-1 non-Nucleoside Reverse Transcriptase Inhibitors. Current Medicinal Chemistry, 2011, 18(16): 2376-2385

    10. Zhang Jing, Ge Weiying, Zhan Peng, De Clercq E, Liu Xinyong*. Retroviral Restriction Factors TRIM5α: Therapeutic Strategy to Inhibit HIV-1 Replication. Curr Med Chem. 2011; 18(17): 2649-2654.

    11. Xuwang Chen, Peng Zhan, Dongyue Li, Erik De Clercq and Xinyong Liu*. Recent Advances in DAPYs and Related Analogues as HIV-1 NNRTIs. Current Medicinal Chemistry, 2011, 18, 359-376

    12. Zhenyu. Li, Peng. Zhan and Xinyong Liu*. 1,3,4-Oxadiazole: A Privileged Structure in Antiviral Agents. Mini-Reviews in Medicinal Chemistry, 2011, 11: 1130-1142

    13. Peng Zhan, Xuwang Chen, Xinyong Liu*, Christophe Pannecouque, Lieve Naesens, Erik De Clercq, Ailin Liu, Guanhua Du. Thiazolylthioacetamides as a Novel Class of Potential Antiviral Agents. Antiviral Research, Volume 90, Issue 2, May 2011, Page A67.

    14. Wenjun Li, Peng Zhan, Jingde Wu, Yu Chang, Christophe Pannecouque, Erik De Clercq, Xinyong Liu.* Synthesis, Influence of Polymer Molecular Weight on Drug Release and Anti-HIV Activity of PEGylated AZT Conjugates. Antiviral Research, Volume 90, Issue 2, May 2011, Page A37.

    15. Peng Zhan, Renzhang Yan, Xinyong Liu,*, Christophe Pannecouque, Myriam Witvrouw , Erik De Clercq, Maria Teresa Molina, Salvador Vega. Synthesis and anti-HIV activity of novel 2,4-disubstituted-7-methyl- 1,1,3-trioxo-2H,4H-pyrazolo[4,5-e] [1,2,4]thiadiazine derivatives. Drug Discoveries & Therapeutics. 2011; 5(6):279-285.2012.01.17出刊

    16. Hu Song-Qing, Mi Si-Qi, Jia Xiao-Lin, Fan Cheng-Cheng, Chen Sheng-Hui, Zhang Jun, Liu Xin-Yong*. 3D-QSAR Study and Molecular Design of Benzimidazole Derivatives as Corrosion Inhibitors. Chemical Journal Of Chinese Universities. 2011, Vol. 32 Issue (10) :2402-2409

    17. Yu-Ning Song, Xiu-Li Guo, Bei-Bei Zheng, Xin-Yong Liu, Xue Dong, Lu-Gang Yu, Yan-Na Cheng. Ligustrazine derivate DLJ14 reduces multidrug resistance of K562/A02 cells by modulating GSTπ activity. Toxicol. Vitro. 2011; vol. 25, no. 4, pp. 937-943,

     

    2010

    1. Wenjun Li, Yu Chang, Peng Zhan, Na Zhang, Xinyong Liu,*Christophe Pannecouque, and Erik De Clercq. Synthesis, In Vitro and In Vivo Release Kinetics, and Anti-HIV Activity of A Sustained-Release Prodrug (mPEG-AZT) of 3’ -Azido -3’ -deoxythymidine (AZT, Zidovudine). ChemMedChem 2010; 5: 1893-1898.

    2. Peng Zhan, Xinyong Liu*, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. 1,2,3-Thiadiazole Thioacetanilides. Part 2. Synthesis and Biological Evaluation of a New Series of 2-(4-(3,4-dichlorophenyl)-1,2,3-Thiadiazol-5-ylthio)Acetamides as Anti-HIV-1 inhibitors. Chemistry & Biodiversity. 2010; 7: 1717-1726

    3.Yang Ou, Xue Dong, Xin-Yong Liu, Xian-Chao Cheng, Yan-Na Cheng, Lu-Gang Yu, and Xiu-Li Guo*. Mechanism of Tetramethylpyrazine Analogue CXC195 Inhibition of Hydrogen Peroxide-Induced Apoptosis in Human Endothelial Cells. Biol. Pharm. Bull. 2010; 33(3): 432-438

    4. Ou Y, Guo XL, Zhai L, Liu XY, Cheng YN. TMPDP, a tetramethylpyrazine derivative, protects vascular endothelial cells from oxidation damage by hydrogen peroxide. Pharmazie. 2010 Oct; 65(10):755-9.

    5. Peng Zhan, Hongbing Liu, Xinyong Liu*, Yan Wang, Christophe Pannecouque, Myriam Witvrouw, Erik De Clercq. Synthesis and anti-HIV activity evaluation of novel N1-arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. Medicinal Chemistry Research. 2010; 19:652–663

    6. Hongfei Chen, Xinyong Liu*, Peng Zhan and Erik De Clercq. TSG101: a Novel Anti-HIV-1 Drug Target. Current Medicinal Chemistry . 2010; 17(8): 750-758

    7. Peng Zhan, Xinyong Liu*, Erik De Clercq. Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. Current Medicinal Chemistry, 2010; 17(6): 495-503 

    8. Peng Zhan, Xuemei Jiang, Xinyong Liu*. Naturally Occurring and Synthetic Bioactive Molecules as Novel Non-nucleoside HBV Inhibitors. Mini-Reviews in Medicinal Chemistry. 2010 Feb;10(2):161-70.

    9. Peng Zhan, Zhenyu Li, Xinyong Liu*. Cosalane and Related Analogues: A Unique Class of Anti-HIV Agents. Mini-Reviews in Medicinal Chemistry, 2010, 10, 966-976

    10.Zhan Peng, Li Wenjun, Chen Hongfei and Liu Xinyong*.Targeting Protein-Protein Interactions: A Promising Avenue of Anti-HIV Drug Discovery. Current Medicinal Chemistry, 2010; 17(6): 495-503 

     

    2009

    1. Peng Zhan, Xinyong Liu*, Zhenyu Li, Zengjun Fang, Zhong Li, Defeng Wang, Christophe Pannecouque, Erik De Clercq. Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: synthesis and preliminary SAR studies. Bioorganic & Medicinal Chemistry, 2009; 17(16): 5920-5927. (15 August 2009).

    2. Mingyan Yu, Xinyong Liu*, Zhenyu Li, Shuai Liu, Christophe Pannecouque, Erik De Clercq Synthesis and biological evaluation of novel 2-(substituted phenylaminocarbonyl methylthio)-6-(2,6-dichlorobenzyl)-pyrimidin-4(3H)-ones as potent HIV-1 NNRTIs. Bioorganic & Medicinal Chemistry, 2009;17: 7749–7754

    3. Peng Zhan, Xinyong Liu*, Junjie Zhu, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. 1,2,3-Selenadiazole thioacetanilides: Synthesis and anti-HIV activity evaluation Bioorg Med Chem. 2009; 17(16): 5733-6146

    4. Peng Zhan, Xinyong Liu*, Junjie Zhu, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem. 2009; 17(16): 5775-5781.

    5. Xinyong Liu*, Peng Zhan, Christophe Pannecouque, Erik De Clercq. Design, Synthesis and Anti-HIV-1 Evaluation of Novel Arylazolylthioacetanilides as Potent NNRTIS.  Antiviral Research, Volume 82, Issue 2, May 2009, Pages A44-A45

    6. Peng Zhan, Xinyong Liu*, Zengjun Fang, Zhenyu Li, Christophe Pannecouque, Erik De Clercq. Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5- ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. European Journal of Medicinal Chemistry, 2009; 44 : 4648–4653

    7.Xian-Chao Cheng, Xin-Yong Liu*, Wen-Fang Xu, Xiu-Li Guo Ning Zhang, Yuning Song Ligustrazine derivatives part 31: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents. Bioorganic & Medicinal Chemistry. 2009; 17: 3018–3024

    8. Yuan Cao, Xinyong Liu* and Erik De Clercq. Cessation of HIV-1 Transcription by Inhibiting Regulatory Protein Rev-Mediated RNA Transport. Current HIV Research, 2009, 7(1):, 101-108

    9. Yu Mingyan, Liu Xinyong* and Erik De Clercq. NF-κB: The Inducible Factors of HIV-1 Transcription and their Inhibitors. Mini-Reviews in Medicinal Chemistry, 2009, 9(1): 60-69

    10. Jiyan Zhang, Xinyong Liu* and Erik De Clercq. Capsid (CA) Protein as a Novel Drug Target: Recent Progress in the Research of HIV-1 CA Inhibitors. Mini-Reviews in Medicinal Chemistry. 2009; Volume 9(4): April, 510-518.

    11. Yan Wang, Xin-yong Liu* and Erik De Clercq. Role of the HIV-1 Positive Elongation Factor P-TEFb and Inhibitors Thereof.  Mini-Reviews in Medicinal Chemistry, 2009, 9(3): 379-385

    12. Peng Zhan and Xinyong Liu*. Designed Multiple Ligands: An Emerging Anti-HIV Drug Discovery Paradigm. Curr Pharm Des. 2009; 36(15): 1893-1917

    13. Peng Zhan, Zhenyu Li, Xinyong Liu* Sulfanyltriazole/tetrazoles: A Promising Class of HIV-1 NNRTIs. Mini-Reviews in Medicinal Chemistry, 2009, 9(8): 1014-1023

    14. Peng Zhan, Xinyong Liu* and Zhanyu Li. Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. Current Medicinal Chemistry, 2009; 16(22): 2876-2889. (August 2009)

    15. Peng Zhan, Xinyong Liu*, Christophe Pannecouque, Erik De Clercq. Design Strategies of Novel NNRTIs to Overcome Drug Resistance. Current Medicinal Chemistry, 2009; 16(29): 3903-3917.

     

    2008

    1. Peng Zhan, Xinyong Liu*, Yuan Cao, Yan Wang, Christophe Pannecouque, Erik De Clercq. 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg Med Chem Lett. 2008; Oct 15;18(20):5368-71.

    2. Peng Zhan, Xinyong Liu* and Erik De Clercq. Recent Advances in Antiviral Activity of Benzo/Heterothiadiazine Dioxide Derivatives. Current Medicinal Chemistry, 2008; 15(15): 1529-1540.

    3. Yongqiang Lin, Xinyong Liu,* Renzhang Yan, Jin Li, Christophe Pannecouque, Myriam Witvrouw and Erik De Clercq* Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides (TTDDs). Bioorganic & Medicinal Chemistry, 2008; 16 (1): 157–163

    4. Xinyong Liu,* Ren-zhang Yan, Yan Wang, Peng Zhan, Christophe Pannecouque, Myriam Witvrouw, Erik De Clercq, Maria Teresa Molina and Salvador Vega. Synthesis and Anti-HIV Activity Evaluation of Novel 2,4-Disubstituted 7-Methyl-1,1,3-trioxo-2H,4H-Pyrazolo[4,5-e] [1,2,4]thiadiazines. Arch.Pharmazie, 2008; 341(4): 216-222

    5. Fang Yu, Xinyong Liu,* Peng Zhan and Erik De Clercq. Recent Advances in the Research of HIV-1 RNase H Inhibitors. Mini-Reviews in Medicinal Chemistry, 2008, Nov; 8(12):1243-51

    6. Xinyong Liu* , Peng Zhan, Renzhang Yan, Yongqiang Lin, Jin Li,Christophe Pannecouque  and Erik De Clercq. Design, Synthesis and Antiviral Evaluation of Novel Heterocyclic Compounds as HIV-1 NNRTIs. Drug Discov Ther 2008;2: 25-28

     

    2007

    1. Xian-Chao Cheng, Xin-Yong Liu,* Wen-Fang Xu, Xiu-Li Guo and Yang Ou. Design, synthesis and biological activities of novel Ligustrazine derivatives. Bioorganic & Medicinal Chemistry 2007; 15(10): 3315–3320

    2. Jingde Wu, Xinyong Liu *, Xianchao Cheng , Yuan Cao, Defeng Wang , Zhong Li, Wenfang Xu , Christophe Pannecouque , Myriam Witvrouw and Erik De Clercq. Synthesis of Novel Derivatives of 4-Amino-3-(2-Furyl)-5-Mercapto-1,2,4-Triazole as Potential HIV-1 NNRTIs. Molecules, 2007, 12(8): 2003-2016.

    3. Xin Yong LIU*, Ren Zhang YAN, Nian Gen CHEN, Wen Fang XU . Regioselective Synthesis and Anti-HIV Activity of the Novel 2- and 4-Substituted Pyrazolo[4,5-e][1,2,4]thiadiazines. Chin. Chem. Lett. 2007;18: 137-140

    4. Xin-Yong Liu*, Xian-Jun Qu, Wei Tang. China-Japan enhance joint research cooperation for drug discoveries and development: News from CJMWDDT 2007 in Jinan , China . Drug Discov Ther 2007;1(1):1

     

    2006

    1. Xinyong Liu* Niangen Chen, Renzhang Yan, Wenfang Xu, Maria Teresa Molina, and Salvador Vega Regioselective Synthesis of the Novel N4-Substituted Pyrazolo[4,5-e][1,2,4] thiadiazines as Potent HIV-1 NNRTIs. Heterocycles, 2006; 68(6): pp.1225-1232

    2. Xinyong Liu*, Renzhang Yan, Niangen Chen, Wenfang Xu, Maria Teresa Molina and Salvador Vega. Regioselective Synthesis of Novel N2- and N4-Substituted 7-Methylpyrazolo [4,5-e] [1,2,4]thiadiazines, Molecules, 2006, 11: 827-836

    3. Xianchao Cheng, Xinyong Liu*, Wenfang Xu. Synthesis of Novel Ligustrazine Derivatives as Potential Platelet Aggregation Inhibitors. Chinese Chemical Letters 2006; Vol. 17, No. 10, pp 1317-1320

    4. Xian-chao Cheng, Xin-yong Liu* and Wen-fang Xu .The preparation of novel ligustrazine derivatives as potential cerebrocardiac vascular agents. Journal of Chemical Research, 2006; September, 577–579

    5. Ren-Zhang Yan, Xin-Yong Liu*, Wen-Fang Xu, Christophe Pannecouque1, Myriam Witvrouw, and Erik De Clercq. Synthesis and Anti-HIV Evaluation of the Novel 2-(m-Chlorobenzyl)-4- substituted-7-methyl-1, 1, 3-trioxo-pyrazolo[4,5-e][1, 2, 4]thiadiazines. Arch Pharm Res, 2006; 29, No 11, 957-962

     

    2005-2003

    1. Xinyong Liu*, Niangen Chen, Yinzhang Yan, Wen-fang Xu. Design and Synthesis of N4-Substituted Pyrazolo[4,5-e][1,2,4] Thiadiazine Derivatives as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors. Chinese Journal of Organic Chemistry. 2005; Vol. 25, Suppl., 701

    2. Xianchao Cheng, Xinyong Liu* Wenfang Xu. Recent advances in the structural modification of ligustrazine; cerebro- and cardiovascular activity of ligustrazine derivatives. Drugs of the Future, 2005; 30(10): 1059.

    3. Xin Yong Liu*, Wen Fang Xu, Jing De Wu. Synthesis of 4-Amino-5-furyl-2-yl-4H-1, 2, 4-triazole-3-thiol Derivatives as a Novel Class of Endothelin(ET) Receptor Antagonists. Chin Chem. Letter (CCL); 2003, 14(8):790-793       

    4. Zeng Bao-Shan, Chen Min-Bo*, Dong Xi-Cheng, Liu Xin-Yong*. q2 Guided Conformation Selection Approach of CoM FA for HIV-1 RT Inhibitors. Acta Chemica Sinica, 2003; 61(7): 1121-1128

    5. Xinyong Liu*, Zhang Rui and Wenfang Xu. Synthesis of The Novel Liqustrazine Derivatives and Their Protective Effect on Injured Vascular Endothelial Cell Damaged by Hydrogen Peroxide.  Bioorg. Med. Chem. Letter; 2003; 13: 2123-2126

     

     


    Powered by :School Of Pharmaceutical Sciences Shandong University Copyright 2007-2013
    Address:44 Wenhuaxi Rd.Jinan,Shandong Tel:0531-88382017 Fax:0531-88382548 E-mail:wangfanfan@sdu.edu.cn